Matching articles for "Xarelto"
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • January 8, 2024; (Issue 1693)
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • July 25, 2022; (Issue 1655)
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines for
treatment of VTE were updated in 2020 and 2021.
Comparison Table: Some Oral Anticoagulants for VTE (online only)
The Medical Letter on Drugs and Therapeutics • July 25, 2022; (Issue 1655)
...
View the Comparison Table: Some Oral Anticoagulants for VTE
Apoaequorin (Prevagen) to Improve Memory
The Medical Letter on Drugs and Therapeutics • November 1, 2021; (Issue 1636)
A synthetic form of the protein apoaequorin is the
active ingredient in the over-the-counter dietary
supplement Prevagen (Quincy Bioscience), which
is heavily marketed to improve...
A synthetic form of the protein apoaequorin is the
active ingredient in the over-the-counter dietary
supplement Prevagen (Quincy Bioscience), which
is heavily marketed to improve memory.
Drugs for Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • September 9, 2019; (Issue 1580)
Treatment of atrial fibrillation includes anticoagulation,
rate control, and rhythm control. US guidelines were
recently...
Treatment of atrial fibrillation includes anticoagulation,
rate control, and rhythm control. US guidelines were
recently updated.
Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
The Medical Letter on Drugs and Therapeutics • December 3, 2018; (Issue 1561)
The FDA has approved a new 2.5-mg formulation of
the direct factor Xa inhibitor rivaroxaban (Xarelto –
Janssen) for use in combination with low-dose aspirin
to reduce the risk of major cardiovascular...
The FDA has approved a new 2.5-mg formulation of
the direct factor Xa inhibitor rivaroxaban (Xarelto –
Janssen) for use in combination with low-dose aspirin
to reduce the risk of major cardiovascular events in
patients with chronic coronary artery disease (CAD)
or peripheral artery disease (PAD). Rivaroxaban is
the first direct oral anticoagulant to be approved for
this indication. It was approved earlier for prevention
and treatment of deep vein thrombosis (DVT) or
pulmonary embolism (PE) and for prevention of stroke
and systemic embolism in patients with nonvalvular
atrial fibrillation.
Andexxa - An Antidote for Apixaban and Rivaroxaban
The Medical Letter on Drugs and Therapeutics • June 18, 2018; (Issue 1549)
Coagulation factor Xa (recombinant), inactivated-zhzo
(andexanet alfa; Andexxa – Portola) has received
accelerated approval from the FDA for urgent reversal
of the anticoagulant effect of the direct factor...
Coagulation factor Xa (recombinant), inactivated-zhzo
(andexanet alfa; Andexxa – Portola) has received
accelerated approval from the FDA for urgent reversal
of the anticoagulant effect of the direct factor Xa
inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto).
Andexanet alfa is the second antidote for a direct oral
anticoagulant to become available in the US, and the
fi rst for factor Xa inhibitors. Idarucizumab (Praxbind)
was approved in 2015 for reversal of the anticoagulant
effect of the direct thrombin inhibitor dabigatran
etexilate (Pradaxa). Andexanet alfa has not been
approved to date for reversal of anticoagulation with
the direct factor Xa inhibitors edoxaban (Savaysa) or
betrixaban (Bevyxxa).
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • March 12, 2018; (Issue 1542)
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). Updated US...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). Updated US guidelines
for treatment of VTE were published in 2016.
Comparison Table: Some Oral Anticoagulants for VTE (online only)
The Medical Letter on Drugs and Therapeutics • March 12, 2018; (Issue 1542)
...
View the Comparison Table: Some Oral Anticoagulants for VTE
Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness
The Medical Letter on Drugs and Therapeutics • January 1, 2018; (Issue 1537)
The FDA has approved betrixaban (Bevyxxa –
Portola), a once-daily, oral, direct factor Xa inhibitor,
for prophylaxis of venous thromboembolism (VTE)
in adults hospitalized for an acute medical illness
who...
The FDA has approved betrixaban (Bevyxxa –
Portola), a once-daily, oral, direct factor Xa inhibitor,
for prophylaxis of venous thromboembolism (VTE)
in adults hospitalized for an acute medical illness
who have moderately or severely restricted mobility
and other risk factors for VTE. Betrixaban is the
first oral anticoagulant to be approved in the US for
this indication.
Anticoagulation of Elderly Patients at High Risk for Falls with Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • February 27, 2017; (Issue 1515)
With the widespread adoption of the CHA2DS2-VASc
scoring system, oral anticoagulation therapy is
now recommended for all patients ≥75 years old
with nonvalvular atrial fibrillation. Atrial...
With the widespread adoption of the CHA2DS2-VASc
scoring system, oral anticoagulation therapy is
now recommended for all patients ≥75 years old
with nonvalvular atrial fibrillation. Atrial fibrillation
has, however, been associated with an increased
risk of falls, and older patients starting warfarin for
atrial fibrillation have a high rate of hospitalization
for intracranial bleeding. Many practitioners are
reluctant, therefore, to prescribe an oral anticoagulant
for elderly patients who are at high risk for falls.
Which Oral Anticoagulant for Atrial Fibrillation?
The Medical Letter on Drugs and Therapeutics • April 11, 2016; (Issue 1492)
Direct-to-consumer advertisements continue to
urge patients who take warfarin (Coumadin, and
others) for atrial fibrillation to ask their doctors
about the benefits of one or another of the newer
oral...
Direct-to-consumer advertisements continue to
urge patients who take warfarin (Coumadin, and
others) for atrial fibrillation to ask their doctors
about the benefits of one or another of the newer
oral anticoagulants.
Idarucizumab (Praxbind) - An Antidote for Dabigatran
The Medical Letter on Drugs and Therapeutics • November 23, 2015; (Issue 1482)
The FDA has approved idarucizumab (Praxbind –
Boehringer Ingelheim) for urgent reversal of the
anticoagulant effect of the direct thrombin inhibitor
dabigatran etexilate (Pradaxa). Idarucizumab is...
The FDA has approved idarucizumab (Praxbind –
Boehringer Ingelheim) for urgent reversal of the
anticoagulant effect of the direct thrombin inhibitor
dabigatran etexilate (Pradaxa). Idarucizumab is the
first specific reversal agent to become available for
one of the new oral anticoagulants.
Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant
The Medical Letter on Drugs and Therapeutics • March 30, 2015; (Issue 1465)
The FDA has approved edoxaban (Savaysa – Daiichi
Sankyo), a once-daily, oral, direct factor Xa inhibitor,
for treatment of venous thromoboembolism (VTE)
and for prevention of stroke and systemic...
The FDA has approved edoxaban (Savaysa – Daiichi
Sankyo), a once-daily, oral, direct factor Xa inhibitor,
for treatment of venous thromoboembolism (VTE)
and for prevention of stroke and systemic embolism
in patients with nonvalvular atrial fibrillation. It is the
fourth new oral anticoagulant to be approved for VTE
and nonvalvular atrial fibrillation.
Antithrombotic Drugs
The Medical Letter on Drugs and Therapeutics • October 27, 2014; (Issue 1454)
Antiplatelet drugs are the drugs of choice for
prevention and treatment of arterial thrombosis.
Anticoagulants are the drugs of choice for prevention
and treatment of venous thromboembolism and...
Antiplatelet drugs are the drugs of choice for
prevention and treatment of arterial thrombosis.
Anticoagulants are the drugs of choice for prevention
and treatment of venous thromboembolism and for
prevention of cardioembolic events in patients with
atrial fibrillation.
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • July 7, 2014; (Issue 1446)
The treatment of atrial fibrillation includes anticoagulation,
rate control, and rhythm control. New US
guidelines for the management of atrial fibrillation
have recently been...
The treatment of atrial fibrillation includes anticoagulation,
rate control, and rhythm control. New US
guidelines for the management of atrial fibrillation
have recently been published.
Rethinking Warfarin for Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • September 30, 2013; (Issue 1426)
Full-page newspaper advertisements and a series of television
commercials have urged patients with atrial fibrillation
to "rethink warfarin" in favor of Eliquis (apixaban –
Bristol-Myers Squibb). Apixaban...
Full-page newspaper advertisements and a series of television
commercials have urged patients with atrial fibrillation
to "rethink warfarin" in favor of Eliquis (apixaban –
Bristol-Myers Squibb). Apixaban is the latest of 3 new oral
anticoagulants now competing with warfarin (Coumadin,
and others) for the oral anticoagulant market.
Kcentra: A 4-Factor Prothrombin Complex Concentrate for Reversal of Warfarin Anticoagulation
The Medical Letter on Drugs and Therapeutics • July 8, 2013; (Issue 1420)
The FDA has approved use of Kcentra (CSL Behring), a
human-derived 4-factor prothrombin complex concentrate
(PCC), for urgent reversal of warfarin anticoagulation
in adults with acute major bleeding. It is...
The FDA has approved use of Kcentra (CSL Behring), a
human-derived 4-factor prothrombin complex concentrate
(PCC), for urgent reversal of warfarin anticoagulation
in adults with acute major bleeding. It is the only
4-factor PCC available in the US.
Apixaban (Eliquis) - A New Oral Anticoagulant for Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • February 4, 2013; (Issue 1409)
The FDA has approved apixaban (Eliquis – Bristol-Myers Squibb/Pfizer), an oral direct factor Xa inhibitor,
for prevention of stroke and systemic embolism in
patients with nonvalvular atrial fibrillation. It...
The FDA has approved apixaban (Eliquis – Bristol-Myers Squibb/Pfizer), an oral direct factor Xa inhibitor,
for prevention of stroke and systemic embolism in
patients with nonvalvular atrial fibrillation. It is the third
new oral anticoagulant to be approved for this indication
as an alternative to warfarin.
Rivaroxaban (Xarelto) for Acute Coronary Syndrome
The Medical Letter on Drugs and Therapeutics • December 12, 2011; (Issue 1379)
The standard antithrombotic therapy for treatment of
patients with acute coronary syndrome (ACS) is dual
antiplatelet therapy with aspirin and clopidogrel (Plavix)
or another thienopyridine, plus a...
The standard antithrombotic therapy for treatment of
patients with acute coronary syndrome (ACS) is dual
antiplatelet therapy with aspirin and clopidogrel (Plavix)
or another thienopyridine, plus a parenteral anticoagulant
while the patient is hospitalized, followed by antiplatelet
therapy alone after discharge. The addition of the oral
anticoagulant warfarin (Coumadin, and others) to dual
antiplatelet therapy is generally not recommended for this
indication because of fluctuations in its anticoagulant
effect and the risk of bleeding. A recently published trial
found that addition of a low dose of the oral anticoagulant
rivaroxaban (Xarelto) to antiplatelet therapy after discharge
reduced the risk of major cardiovascular events
without increasing the incidence of fatal bleeding.
Antithrombotic Drugs
The Medical Letter on Drugs and Therapeutics • October 1, 2011; (Issue 110)
Arterial thrombi are composed mainly of platelet
aggregates held together by small amounts of fibrin.
Antiplatelet drugs are the drugs of choice for prevention
and treatment of arterial thrombosis, but...
Arterial thrombi are composed mainly of platelet
aggregates held together by small amounts of fibrin.
Antiplatelet drugs are the drugs of choice for prevention
and treatment of arterial thrombosis, but anticoagulants
are also effective, and their effects can add to those of
antiplatelet drugs. Venous thrombi are composed
mainly of fibrin and trapped red blood cells, with relatively
few platelets. Anticoagulants are the agents of
choice for prevention and treatment of venous thromboembolism
and for prevention of cardioembolic
events in patients with atrial fibrillation.
Rivaroxaban (Xarelto) - A New Oral Anticoagulant
The Medical Letter on Drugs and Therapeutics • August 22, 2011; (Issue 1371)
The FDA has approved rivaroxaban (Xarelto –
Janssen), an oral direct factor Xa inhibitor, for prevention
of deep vein thrombosis (DVT) in patients undergoing
knee or hip replacement...
The FDA has approved rivaroxaban (Xarelto –
Janssen), an oral direct factor Xa inhibitor, for prevention
of deep vein thrombosis (DVT) in patients undergoing
knee or hip replacement surgery.
Desirudin (Iprivask) for DVT Prevention
The Medical Letter on Drugs and Therapeutics • November 1, 2010; (Issue 1350)
The injectable direct thrombin inhibitor desirudin (Iprivask – Canyon), a recombinant analog of hirudin,
the leech anticoagulant protein, was approved by the FDA in 2003 for prevention of venous...
The injectable direct thrombin inhibitor desirudin (Iprivask – Canyon), a recombinant analog of hirudin,
the leech anticoagulant protein, was approved by the FDA in 2003 for prevention of venous thromboembolism (VTE) after elective hip arthroplasty, but was only marketed recently in the US. It has been available in Europe as Revasc for about 10 years. Two other hirudin analogs are available in the US: lepirudin (Refludan) for treatment of heparin-induced thrombocytopenia (HIT) and bivalirudin (Angiomax) for use in percutaneous coronary intervention (PCI).
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • September 1, 2010; (Issue 97)
The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals...
The treatment of atrial fibrillation includes ventricular rate control, anticoagulation, conversion to normal sinus rhythm and maintenance of sinus rhythm. The choice of therapies that can achieve these goals is discussed in the text that follows. Some drugs are recommended here for indications that have not been approved by the FDA.
Prevention of Venous Thromboembolism in Orthopedic Surgery
The Medical Letter on Drugs and Therapeutics • November 3, 2008; (Issue 1298)
Major orthopedic surgery creates a prothrombotic state by causing tissue injury during the operation and requiring relative immobilization during recovery. Without thromboprophylaxis, 40-60% of patients...
Major orthopedic surgery creates a prothrombotic state by causing tissue injury during the operation and requiring relative immobilization during recovery. Without thromboprophylaxis, 40-60% of patients undergoing major knee or hip surgery develop venographically detectable deep vein thrombosis (DVT) and 1 in 300 undergoing total hip replacement will have a symptomatic pulmonary embolism (PE). Thromboprophylaxis reduces the incidence of venous thromboembolism (VTE), but it also can cause bleeding. New guidelines for prevention of VTE have recently been published.